Frontlight ResearchEarly access
Not yet recruitingPhase 2
Study 3: Ceftazidime/Avibactam Subcutaneous Administration
Key facts
- Who runs it
- Azienda Sanitaria Universitaria Friuli Centrale
- Where
- Italy3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 45 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 1 Apr 2028
- Type of study
- Interventional
- Record updated
- 9 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Free, written and informed consent signed by the participant before any study-specific procedure. • At least 18 years old on the day of inclusion. • Male or female participant. • Hospitalized in a medical ward (not ICU) authorized for enrolment in the study. • Clinical indication for treatment with ceftazidime/avibactam, according to the treating physician and local antimicrobial practice. • Initial intravenous ceftazidime/avibactam treatment started before enrolment or as part of the protocol Day 1 to Day 3 phase, with the patient considered eligible for subsequent switch to subcutaneous administration according to the study design. • Creatinine clearance >50 mL/min at eligibility confirmation. For women of childbearing potential, negative pregnancy test before enrolment according to institutional procedures
Who cannot take part
- Known hypersensitivity to ceftazidime, avibactam, cephalosporins, other beta-lactam antibiotics, beta-lactamase inhibitors, or any component of the formulation. • Pregnant or breastfeeding women, or women intending to become pregnant during the study period. • No ongoing clinical indication for ceftazidime/avibactam treatment at the time of eligibility confirmation. • Known microbiological resistance to ceftazidime/avibactam when microbiological results are available before enrolment and the investigator considers CAZ-AVI no longer appropriate. • Creatinine clearance <=50 mL/min at eligibility confirmation. • Admission to an intensive care unit. • Initiation of invasive or non-invasive mechanical ventilation. • Initiation of renal replacement therapy or dialysis. • Initiation of vasopressor support with norepinephrine/noradrenaline or an equivalent vasopressor. • Any clinical condition, physical examination finding, metabolic dysfunction, or laboratory abnormality that contraindicates CAZ-AVI treatment, may interfere with interpretation of study results, or may expose the participant to unacceptable risk according to the investigator. • Inability to comply with study procedures or follow-up requirements
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
TDM of free ceftazidime concentrations on Days 3, 5, 7, and 10, with concurrent creatinine measurements.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 9 November 2026